Xinteza is developing advanced proprietary biosynthesis and bioextraction technologies related to the production of cannabinoid-based active pharmaceutical ingredients (APIs) for the pharmaceutical and food industries. The company is engaged in the research and discovery of a wide array of new genes and ultra-novel genetic paths for the biosynthesis of cannabinoids and psychoactive ingredients and the development of their bioproduction methods. Xinteza holds the exclusive license for both cannabinoids and psychoactives from the Weizmann Institute and is building an exceptional portfolio of dozens of related IP and patents.